GALNS


Also found in: Dictionary, Thesaurus, Legal, Encyclopedia.

GALNS

A gene on chromosome 16q24.3 that encodes N-acetylgalactosamine-6-sulfatase, a lysosomal exohydrolase required for the degradation of glycosaminoglycans, keratan sulfate and chondroitin 6-sulfate.

Molecular pathology
Defects of GALNS cause Morquio A syndrome, a lysosomal storage disease.
References in periodicals archive ?
Incubation of the substrate with a DBS leads to enzymatic release of the sulfate group to produce the GALNS product (GALNS-P) (Fig.
The postassay purification step is imperative because the presence of buffer salts in high concentrations will interfere with the ESI and because the unreacted sulfated substrate can dissociate in the source of the mass spectrometer to form GALNS-P ions, thereby giving rise to false-positive GALNS activity.
La cantidad de 4-metilumbelifarona liberada es directamente proporcional a la cantidad de GALNS presente en la muestra analizada.
Los valores se reportaron como la relacion de la densidad de la banda de GALNS Vs.
In this report, we discuss the rationale for GALNS in MPS IVA, results from BioMarin's completed phase I/II trial, and the potential outcomes in phase III with respect to approval and commercialization.
30 November 2011 - BioMarin Pharmaceuticals (NASDAQ:BMRN) said on Tuesday that it had launched its Phase II study for GALNS (N-acetylgalactosamine 6-sulfatase) in patients under five years of age with mucopolysaccharidosis IVA (MPS IVA).
During the dose escalation phase of the study, subjects receive weekly intravenous infusions of GALNS in three consecutive 12-week dosing intervals: 0.
Biopharmaceuticals company BioMarin Pharmaceutical Inc (Nasdaq:BMRN) reported on Thursday the completion of the enrollment for its pivotal Phase 3 trial of GALNS for lysosomal storage disorder Mucopolysaccharidosis Type IVA.
M2 EQUITYBITES-November 30, 2011-BioMarin Pharmaceutical Inc commences Phase 2 study of GALNS for MPS IVA treatment(C)2011 M2 COMMUNICATIONS http://www.